- Home
- FFC vs VIR Comparison
FFC vs VIR Comparison
Compare FFC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFC | VIR |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.3M | 825.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FFC | VIR |
|---|---|---|
| Price | $16.52 | $5.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.73 |
| AVG Volume (30 Days) | 164.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.90 | $4.16 |
| 52 Week High | $14.96 | $14.45 |
Technical Indicators
Market Signals| Indicator | FFC | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 49.01 |
| Support Level | $16.43 | $5.55 |
| Resistance Level | $16.67 | $6.10 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 30.77 | 37.92 |
Price Performance
Historical ComparisonAbout FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.